The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review

References

• Redmond GP. Androgens and women’s health. Int J Fertil Womens Med. 1998;43:91–97.
   PubMedGoogle Scholar
• Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez L, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453–462.
   PubMed Web of Science ®Google Scholar
• Ekbäck MP, Lindberg M, Benzein E, et al. Health-related quality of life, depression and anxiety correlate with the degree of hirsutism. Dermatology (Basel). 2013;227:278–284.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846–850.
   PubMed Web of Science ®Google Scholar
• Ozdemir S, Ozdemir M, Görkemli H, et al. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89:199–204.
   PubMed Web of Science ®Google Scholar
• Orfanos CE. Antiandrógenos en Dermatologí. Arch Arg Derm. 1982;32:51–55.
   Google Scholar
• Orfanos CE, Adler YID, Zouboulis CC. The SAHA syndrome. Horm Res. 2000;54:251–258.
   PubMed Web of Science ®Google Scholar
• Dianette Summary of Product Characteristics; 2017. Available from: http://www.medicines.org.uk/emc/medicine/1814/SPC/dianette/.
   Google Scholar
• Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98:1053–1059.
   PubMed Web of Science ®Google Scholar
• Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol. 1994;102:1–32.
   PubMedGoogle Scholar
• Spona J, Huber J. Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate. Gynecol Obstet Invest. 1987;23:184–193.
   PubMed Web of Science ®Google Scholar
• Fang S, Liao S. Antagonistic action of anti-androgens on the formation of a specific dihydrotestosterone-receptor protein complex in rat ventral prostate. Mol Pharmacol. 1969;5:428–431.
   PubMed Web of Science ®Google Scholar
• Fedele L, Marchini M, Cavalli G, et al. Marked deciliation and insufficient secretory modification of endometrial surface during treatment with a new progestogen–estrogen combination. Contraception. 1987;35:497–505.
   PubMed Web of Science ®Google Scholar
• Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens – a short review. Postgrad Med J. 1978;54:11–24.
   PubMed Web of Science ®Google Scholar
• Aydinlik S, Kaufman J, Lachnit-Fixson U, et al. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination. Clin Trials J. 1990;27:392–402.
   Google Scholar
• Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68:891–905.
   PubMed Web of Science ®Google Scholar
• Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003;4:CD001125.
   Google Scholar
• Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425. doi: 10.1002/14651858.
   PubMedGoogle Scholar
• van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;4:CD010334. doi: 10.1002/14651858.CD010334.pub2.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1–9.
   PubMed Web of Science ®Google Scholar
• Collins JA, Fauser CJMB. Balancing the strengths of systematic and narrative reviews. Hum Reprod Update. 2005;11:103–104.
   PubMed Web of Science ®Google Scholar
• Ferrari R. Writing narrative style literature reviews. Medical Writing. 2015;24:230–235.
   Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447.
   PubMed Web of Science ®Google Scholar
• Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–830.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf). 2002;57:231–234.
   PubMed Web of Science ®Google Scholar
• Fugère P, Percival-Smith RK, Lussier-Cacan S, et al. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose–response study of the estrogen component. Contraception. 1990;42:225–234.
   PubMed Web of Science ®Google Scholar
• Palombo-Kinne E, Schellschmidt I, Schumacher U, et al. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009;79:282–289.
   PubMed Web of Science ®Google Scholar
• Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care. 2001;6:46–53.
   PubMed Web of Science ®Google Scholar
• Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl. 1986;134:29–32.
   PubMedGoogle Scholar
• Greenwood R, Brummitt L, Burke B, et al. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen–cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed). 1985;291:1231–1235.
   PubMed Web of Science ®Google Scholar
• Dieben TO, Vromans L, Theeuwes A, et al. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception. 1994;50:373–382.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod. 1997;12:663–666.
   PubMed Web of Science ®Google Scholar
• Belisle S, Love EJ. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil Steril. 1986;46:1015–1020.
   PubMed Web of Science ®Google Scholar
• Sert M, Tetiker T, Kirim S. Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. Acta Med Okayama. 2003;57:73–76.
   PubMed Web of Science ®Google Scholar
• Sahin Y, Dilber S, Keleştimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2001;75:496–500.
   PubMed Web of Science ®Google Scholar
• Keleştimur F, Sahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril. 1998;69:66–69.
   PubMed Web of Science ®Google Scholar
• Porcile A, Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril. 1991;55:877–881.
   PubMed Web of Science ®Google Scholar
• Ibanez L, Diaz M, Sebastiani G, et al. Treatment of androgen excess in adolescent girls: ethinylestradiol–cyproteroneacetate versus loq-does pioglitazone-flutamide-metformin. J Clin Endocrinol Metab. 2011;96:3361–3366.
   PubMed Web of Science ®Google Scholar
• van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69:2–15.
   PubMedGoogle Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85:3161–3168.
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Landin K, Krotkiewski M, et al. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998;13:2706–2711.
   PubMed Web of Science ®Google Scholar
• Gokmen O, Senoz S, Gulekli B, et al. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol. 1996;10:249–255.
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4116–4123.
   PubMed Web of Science ®Google Scholar
• Kahraman K, Sükür YE, Atabekoğlu CS, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet. 2014;290:321–328.
   PubMed Web of Science ®Google Scholar
• Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci. 2000;900:245–252.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:2453–2461.
   PubMed Web of Science ®Google Scholar
• Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod. 2006;21:121–128.
   PubMed Web of Science ®Google Scholar
• Falsetti L, Pasinetti E, Ceruti D. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism. Acta Eur Fertil. 1994;25:303–306.
   PubMedGoogle Scholar
• Golland IM, Elstein ME. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:263–271.
   PubMed Web of Science ®Google Scholar
• De Leo V, Fulghesu AM, la Marca A, et al. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. Gynecol Endocrinol. 2000;14:411–416.
   PubMed Web of Science ®Google Scholar
• Erkkola R, Hirvonen E, Luikku J, et al. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990;69:61–65.
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;85:420–427.
   Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Deligeoroglou E, et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril. 2006;77:919–927.
   Web of Science ®Google Scholar
• Tartagni M, Schonauer LM, De Salvia MA, et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2000;73:718–723.
   PubMed Web of Science ®Google Scholar
• Acién P, Mauri M, Gutierrez M. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms. Hum Reprod. 1997;12:423–429.
   PubMed Web of Science ®Google Scholar
• Chung JP, Yiu AK, Chung TK, et al. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2014;27:166–171.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Benefits of Diane 35 and its generics outweigh risks in certain patient groups – PRAC recommendation endorsed by CMDh. EMA/31830/2013; 2013.
   Google Scholar
• Fugere P, Percival-Smith RKL, Cacan SL, et al. Cyproterone acetate/ethinyl estradiol in the treatment of acne. Comparative dose-response study of the estrogen component. Contraception. 1990;40:225–234.
   Web of Science ®Google Scholar
• Ruan X, Mueck AO, Aguilar A, Kubba A. Use of cyproterone acetate/ethinyl estradiol in polycystic ovary syndrome: rationale and practical aspects. 2016, in press.
   Google Scholar
• Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007;30:471–478.
   PubMed Web of Science ®Google Scholar
• Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84:1304–1310.
   PubMed Web of Science ®Google Scholar
• Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril. 2005;84:1693–1697.
   PubMed Web of Science ®Google Scholar
• Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil. 1996;41:423–429.
   Google Scholar
• Miller JA, Wojnarowska FT, Dowd PM, et al. Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol. 1986;114:705–716.
   PubMed Web of Science ®Google Scholar
• Colver GB, Mortimer PS, Dawber RPR. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol. 1988;118:95–99.
   PubMed Web of Science ®Google Scholar
• Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol. 2007;23:38–44.
   PubMed Web of Science ®Google Scholar
• Barth JH, Cherry CA, Wojnarowska F, Dawber RPR. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol. 1991;35:5–10.
   PubMed Web of Science ®Google Scholar
• Taner C, Inal M, Basogul Ö, et al. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet Invest. 2002;54:105–108.
   PubMed Web of Science ®Google Scholar
• Vegetti W, Testa G, Maggioni P, et al. An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism. Gynecol Obstet Invest. 1996;41:260–268.
   PubMed Web of Science ®Google Scholar
• Karakurt F. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. Adv Ther. 2008;25:321–328.
   PubMed Web of Science ®Google Scholar
• Couzinet B, Le Strat N, Brailly S, Schaison G. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J Clin Endocrinol Metab. 1986;63:1031–1035.
   PubMed Web of Science ®Google Scholar